192 related articles for article (PubMed ID: 1478406)
1. [Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial].
Ngô Y; Gélinet JM; Ivanovic A; Kac J; Schénowitz G; Vilotte J; Rambaud JC
Gastroenterol Clin Biol; 1992; 16(10):782-6. PubMed ID: 1478406
[TBL] [Abstract][Full Text] [Related]
2. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group.
d'Albasio G; Paoluzi P; Campieri M; Bianchi Porro G; Pera A; Prantera C; Sturniolo GC; Miglioli M
Am J Gastroenterol; 1998 May; 93(5):799-803. PubMed ID: 9625131
[TBL] [Abstract][Full Text] [Related]
3. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
[TBL] [Abstract][Full Text] [Related]
4. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial.
D'Arienzo A; Panarese A; D'Armiento FP; Lancia C; Quattrone P; Giannattasio F; Boscaino A; Mazzacca G
Am J Gastroenterol; 1990 Sep; 85(9):1079-82. PubMed ID: 2202199
[TBL] [Abstract][Full Text] [Related]
5. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial.
Campieri M; De Franchis R; Bianchi Porro G; Ranzi T; Brunetti G; Barbara L
Scand J Gastroenterol; 1990 Jul; 25(7):663-8. PubMed ID: 2204103
[TBL] [Abstract][Full Text] [Related]
6. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
8. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis.
Hanauer S; Good LI; Goodman MW; Pizinger RJ; Strum WB; Lyss C; Haber G; Williams CN; Robinson M
Am J Gastroenterol; 2000 Jul; 95(7):1749-54. PubMed ID: 10925979
[TBL] [Abstract][Full Text] [Related]
9. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
10. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
11. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
12. Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.
Bianchi Porro G; Ardizzone S; Petrillo M; Fasoli A; Molteni P; Imbesi V
Am J Gastroenterol; 1995 May; 90(5):736-9. PubMed ID: 7733079
[TBL] [Abstract][Full Text] [Related]
13. [Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy].
Freund U; Schölmerich J; Siems H; Kluge F; Schäfer HE; Wannenmacher M
Strahlenther Onkol; 1987 Oct; 163(10):678-80. PubMed ID: 3313776
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
15. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
16. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
d'Albasio G; Pacini F; Camarri E; Messori A; Trallori G; Bonanomi AG; Bardazzi G; Milla M; Ferrero S; Biagini M; Quaranta S; Amorosi A
Am J Gastroenterol; 1997 Jul; 92(7):1143-7. PubMed ID: 9219787
[TBL] [Abstract][Full Text] [Related]
18. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
19. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
Watanabe M; Nishino H; Sameshima Y; Ota A; Nakamura S; Hibi T
Aliment Pharmacol Ther; 2013 Aug; 38(3):264-73. PubMed ID: 23734840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]